| Phenotype | CKDi25 cases defined as >25% eGFRcrea decline during follow-up together with a movement from eGFRcrea≥60 mL/min/1.73m^2 at baseline to eGFR<60 mL/min/1.73m^2 at follow up compared to CKDi25 controls defined as eGFRcrea≥60 mL/min/1.73m^2. High risk groups had 8-14 adverse alleles. Low risk groups had 0-5 adverse alleles. |
| Sample Ancestry | European |
| Total number | 11,440 individuals |
| Detailed numbers |
448 cases (3.92%)
10,992 controls
|
| Number of Cohort(s) | 3 |
| Cohort Short Name | Cohort Full Name | Previous/other/additional names (e.g. sub-cohorts) |
|---|---|---|
| DIACORE | DIAbetes COhoRtE | — |
| KORA | Cooperative Health Research in the Region of Augsburg | KORA F3, KORA F4, KORA S3, KORA S4 |
| UKB | UK Biobank | — |
87.61% overlap between the CKDi25 GWAS cohort and this dataset.